-
Je něco špatně v tomto záznamu ?
Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases
K. Prajzlerová, L. Šenolt, M. Filková
Status neindexováno Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2014
Free Medical Journals
od 2014
PubMed Central
od 2014
Europe PubMed Central
od 2014
Open Access Digital Library
od 2014-09-01
ROAD: Directory of Open Access Scholarly Resources
od 2014
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
MicroRNAs (miRNAs) are small non-coding single-stranded RNAs of about 22 nucleotides in length that act as post-transcriptional regulators of gene expression. Depending on the complementarity between miRNA and target mRNA, cleavage, destabilization, or translational suppression of mRNA occurs within the RISC (RNA-induced silencing complex). As gene expression regulators, miRNAs are involved in a variety of biological functions. Dysregulation of miRNAs and their target genes contribute to the pathophysiology of many diseases, including autoimmune and inflammatory disorders. MiRNAs are also present extracellularly in their stable form in body fluids. Their incorporation into membrane vesicles or protein complexes with Ago2, HDL, or nucleophosmin 1 protects them against RNases. Cell-free miRNAs can be delivered to another cell in vitro and maintain their functional potential. Therefore, miRNAs can be considered mediators of intercellular communication. The remarkable stability of cell-free miRNAs and their accessibility in body fluid makes them potential diagnostic or prognostic biomarkers and potential therapeutic targets. Here we provide an overview of the potential role of circulating miRNAs as biomarkers of disease activity, therapeutic response, or diagnosis in rheumatic diseases. Many circulating miRNAs reflect their involvement in the pathogenesis, while for plenty, their pathogenetic mechanisms remain to be explored. Several miRNAs described as biomarkers were also shown to be of therapeutic potential, and some miRNAs are already tested in clinical trials.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23015819
- 003
- CZ-PrNML
- 005
- 20231020093651.0
- 007
- ta
- 008
- 231010s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.gendis.2022.08.011 $2 doi
- 035 __
- $a (PubMed)37397550
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Prajzlerová, Klára $u Institute of Rheumatology, Prague 12800, Czech Republic
- 245 10
- $a Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases / $c K. Prajzlerová, L. Šenolt, M. Filková
- 520 9_
- $a MicroRNAs (miRNAs) are small non-coding single-stranded RNAs of about 22 nucleotides in length that act as post-transcriptional regulators of gene expression. Depending on the complementarity between miRNA and target mRNA, cleavage, destabilization, or translational suppression of mRNA occurs within the RISC (RNA-induced silencing complex). As gene expression regulators, miRNAs are involved in a variety of biological functions. Dysregulation of miRNAs and their target genes contribute to the pathophysiology of many diseases, including autoimmune and inflammatory disorders. MiRNAs are also present extracellularly in their stable form in body fluids. Their incorporation into membrane vesicles or protein complexes with Ago2, HDL, or nucleophosmin 1 protects them against RNases. Cell-free miRNAs can be delivered to another cell in vitro and maintain their functional potential. Therefore, miRNAs can be considered mediators of intercellular communication. The remarkable stability of cell-free miRNAs and their accessibility in body fluid makes them potential diagnostic or prognostic biomarkers and potential therapeutic targets. Here we provide an overview of the potential role of circulating miRNAs as biomarkers of disease activity, therapeutic response, or diagnosis in rheumatic diseases. Many circulating miRNAs reflect their involvement in the pathogenesis, while for plenty, their pathogenetic mechanisms remain to be explored. Several miRNAs described as biomarkers were also shown to be of therapeutic potential, and some miRNAs are already tested in clinical trials.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Šenolt, Ladislav $u Institute of Rheumatology, Prague 12800, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague 12800, Czech Republic
- 700 1_
- $a Filková, Mária $u Institute of Rheumatology, Prague 12800, Czech Republic $u Department of Rheumatology, First Faculty of Medicine, Charles University, Prague 12800, Czech Republic
- 773 0_
- $w MED00213968 $t Genes & diseases $x 2352-3042 $g Roč. 10, č. 4 (2023), s. 1263-1278
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37397550 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231010 $b ABA008
- 991 __
- $a 20231020093644 $b ABA008
- 999 __
- $a ok $b bmc $g 1997282 $s 1202181
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 10 $c 4 $d 1263-1278 $e 20220907 $i 2352-3042 $m Genes & diseases $n Genes Dis $x MED00213968
- LZP __
- $a Pubmed-20231010